Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.
about
Computational Approaches for the Discovery of Human Proteasome Inhibitors: An OverviewBreakdown of Immune Tolerance in Systemic Lupus Erythematosus by Dendritic CellsSmall molecules in the treatment of systemic lupus erythematosusProteasome inhibitors in progressive renal diseasesA Minimal β-Lactone Fragment for Selective β5c or β5i Proteasome InhibitorsCause and consequences of the activated type I interferon system in SLEEmerging therapies for systemic lupus erythematosus--focus on targeting interferon-alphaThe ubiquitin proteasome system and myocardial ischemiaThe Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes.Hepatic expression profiles in retroviral infection: relevance to drug hypersensitivity risk.The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosusThe protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina.New insights into B cell biology in systemic lupus erythematosus and Sjögren's syndromeSubunit specific inhibitors of proteasomes and their potential for immunomodulationNFκB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG.Maternal Anti-Fetal Brain IgG Autoantibodies and Autism Spectrum Disorder: Current Knowledge and its Implications for Potential TherapeuticsAnalyzing pathogenic (double-stranded (ds) DNA-specific) plasma cells via immunofluorescence microscopy.Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.Inhibiting the immunoproteasome exacerbates the pathogenesis of systemic Candida albicans infection in mice.Treatment targets in systemic lupus erythematosus: biology and clinical perspective.Plasmacytoid dendritic cells in HIV infection.Protein kinase Cβ is required for lupus development in Sle miceInhibitors of the immunoproteasome: current status and future directionsDrugs in early clinical development for Systemic Lupus Erythematosus.The immunoproteasome as a target in hematologic malignancies.Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice.Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis.Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche.Proteasome inhibitors: an expanding army attacking a unique target.Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?Disease mechanisms in rheumatology--tools and pathways: plasmacytoid dendritic cells and their role in autoimmune rheumatic diseases.B cell biology: implications for treatment of systemic lupus erythematosus.New approaches for the treatment of lupus nephritis in the 21st century: from the laboratory to the clinic.Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.Emerging immunotherapies for rheumatoid arthritis.Peptide-based proteasome inhibitors in anticancer drug design.Update on B-cell targeted therapies for systemic lupus erythematosus.Emerging biological therapies for systemic lupus erythematosus.Signaling mechanisms regulating B-lymphocyte activation and tolerance.
P2860
Q26738752-FBC56BD9-FB05-4172-9C10-631180434464Q26748941-69365FA7-EB40-4F21-B704-C649F0B21A56Q27010090-DE3EAD39-1E26-4EFE-BFB9-11F5CCD95988Q27011485-9929BFD3-0AE2-4995-9DD9-13202E25063EQ27700842-DA145D27-3F52-4706-A79E-C717FF15B230Q28075268-704FAC8F-1B78-4FD3-A96F-32B9C2FF607EQ28265144-1AE4FCB3-5235-4FDA-B596-B583F3BB7D10Q28280898-76C36F8E-0B4C-4968-8A78-8E9103AEAEC1Q33559343-4E4A64FE-9441-451F-90EC-DFDB9FFC5910Q33777950-B62C6FFF-81D7-47F5-807F-5ABFD64E4AAAQ34464260-27F4DFD1-4851-45D8-ABD8-1D40DC744A0AQ34731408-7C8783F8-76A7-4AE0-A2C9-55B577E67F4CQ36011177-565ABA4B-2FEE-489F-B2F1-F39384DCF3B3Q36042649-0DBBAA2E-6513-49E5-9DDD-600B0FB4A2BEQ36110806-A2721B99-A08D-407A-8C67-A5A24F2E171CQ36161935-9E2DAE92-278E-4EF1-B3AA-D8184DE8B050Q36202325-67E9943D-8D90-461E-8858-93ED44F730C2Q36354644-155E1197-1049-405A-A7A3-1B9851B43ED6Q36500101-D7C80DD3-6F27-43A7-AB66-752A7450FC46Q36504624-1D6FA758-0989-40FD-AF7F-1A8263F7E000Q37019332-B3C8A2F4-DE68-4F29-AAF5-9E6FDF963BB4Q37146459-46F57470-6D1D-4E57-9F6D-0F4ED0471A0EQ37292307-90888204-78E9-4E8E-AE58-9F664A9F110DQ37324772-AABC874B-168D-4EAB-AF78-477138708267Q37393379-4113BD79-CCD9-4949-858C-B5D8B8863D69Q37550051-6AA376B1-AE33-4119-A150-BD6693D4D320Q37591113-9BC3BDAC-71A9-4B7A-A905-CD73273BE2DEQ37662690-70FD0EFC-DF7A-4E33-B96B-C03B4FADD8BFQ37979388-39BDA5C7-E136-47C3-925B-F6741C540370Q38019864-483C8DA0-0793-4ABF-8417-CB7A72F076ECQ38068534-32DCD906-3187-4F6D-B616-B183A03BCA1CQ38070990-608879D2-90F3-4492-B15F-43AA64FA7EB1Q38095860-48C94E59-2BAC-423D-A1F9-D467DC2ADEBCQ38148585-B34E5A3D-55FF-4581-8AD9-5E16300C4FE5Q38150110-08117E34-6144-473E-AA59-59EC679BF350Q38188862-A424DD02-9311-4366-823E-2B666C7539DBQ38192572-16FBF3E3-6C7B-410B-A350-9E54CF858FD6Q38192656-18396260-214F-40C6-A49E-0C1E3CAE664FQ38192683-D2EF3C3A-73F5-41A3-9212-063E6D6ABCD5Q38334794-F6E11A57-7191-477A-9A45-301E8F5B0A96
P2860
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Beneficial effect of novel pro ...... autoantibody-secreting cells.
@ast
Beneficial effect of novel pro ...... autoantibody-secreting cells.
@en
type
label
Beneficial effect of novel pro ...... autoantibody-secreting cells.
@ast
Beneficial effect of novel pro ...... autoantibody-secreting cells.
@en
prefLabel
Beneficial effect of novel pro ...... autoantibody-secreting cells.
@ast
Beneficial effect of novel pro ...... autoantibody-secreting cells.
@en
P2093
P2860
P356
P1476
Beneficial effect of novel pro ...... autoantibody-secreting cells.
@en
P2093
Bruce I Goldman
Christopher J Kirk
H Travis Ichikawa
Jennifer Barnard
Jennifer H Anolik
Jing Jiang
R John Looney
Sarah Nevarez
Teresa Owen
P2860
P304
P356
10.1002/ART.33333
P577
2012-02-01T00:00:00Z